U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891417) titled 'Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years' on March 17.
Brief Summary: The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to 29 years.
This study will consist of 3 Sentinel Cohorts and a Main Cohort, with the Sentinel Cohorts assessing the safety of the different dose levels in a stepwise manner.
All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected dur...